Viaderma Inc (OTCMKTS: VDRM) is an exciting biotech currently making a big move up the charts in recent weeks from a start point off its 52-week lows of $0.044 VDRM has rocketed over a penny and is now moving up in copperland. The move up comes as Viaderma continues to put out solid news reporting earlier this week the Company has submitted its application for its planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and the Company expects this process to be completed within a few weeks.
VDRM saw a huge run back in early 2021 from well under a penny to highs over $0.07 and investors are looking for a return to these levels. The Company continues to make progress recently launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra. Viaderma also expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. ViaDerma receives $5,000 per month for each state in which the licensee is doing business and the new states increases ViaDerma’s current royalties to $55,000 per month from this agreement. We will be updating on VDRM when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Viaderma Inc
(OTCMKTS: VDRM) is a specialty pharmaceutical company committed to bringing the best new products to market through many years of innovative clinical research, testing & product development. ViaDerma licenses products in the fields of medicine ranging from infectious diseases to wound care, skin care, CBD, cosmetics, and more. In addition to licensing our proprietary transdermal technologies, our lead product Vitastem is available for treating multiple skin conditions & ailments. Lots of things are happeninng at VDRM including a new corporate website here: ViaDerma.com.
ViaDerma’s lead product Vitastem utilizes an innovative transdermal delivery method to apply any active ingredient to a topical drug. This unique dual carrier transdermal technology can be applied into products within the medical and cosmetics markets. Vitastem is one of the best and most powerful topical antibiotics in the world. With over 10 years of rigorous clinical testing, multiple patents, and more – ViaDerma has produced the most advanced transdermal delivery system that treats numerous infectious diseases far better and faster than any products currently on the market. Recently the Company launched a new and improved formula for Vitastem that is clear and colorless compared to the brownish color of the original, so it will not stain the skin, fingernails, toenails, or anywhere else it is applied.
ViaDerma’s other product Vitastem Ultra uses bacitracin instead of tetracycline. This provides an alternative for people who are allergic to tetracycline, as well as a way to treat tetracycline resistant bacteria. Additionally, Vitastem Ultra will open new doors overseas in many markets that prefer tetracycline alternatives. Like the new and improved Vitastem, Vitastem Ultra is colorless and non-staining. Batches of the new products are currently being produced and are expected to be available to consumers on Amazon, Vitastem.net and other ViaDerma resellers by mid-October.
ViaDerma’s unique transdermal delivery system facilitates the transfer of chemicals through the stratum corneum, the outermost layer of the skin with a diffusion constant that is 10,000x higher than other products on the market. This allows much more of the active ingredient to be absorbed into the skin and work better and faster, often producing significantly better results than traditional topical treatments.
$VDRM, the TDD, transdermal drug delivery
market Dr. Otiko has a "propriety dual delivery
application patent pending" market is endless.
$30B in 2023 & growing each year to over
$60+B in 2030. @IntentSciences will help$VDRM grow profits for years to come! pic.twitter.com/m4ycMKEULJ— M_M7 (@bluegrass_otc) March 13, 2023
To Find out the inside Scoop on VDRM Subscribe to Newsytrends.com Right Now by entering your Email in the box below
ViaDerma is currently in the process of seeking approval for insurance coverage benefits for Vitastem and Vitastem Ultra. Many insurance companies including Medicare and Medicaid offer over-the-counter benefits (OTC) for non-prescription or OTC products such as the products offered by ViaDerma.
Earlier in March VDRM launched a new hair regrowth product using Minoxidil. The company will incorporate their proprietary, patent-pending dual carrier transdermal delivery technology with Minoxidil to create their new hair regrowth product. The global hair restoration market as a whole which includes surgical and noninvasive treatments is expected to reach USD 13.6 billion by 2028, according to this research report by Grand View Research. Minoxidil is the active ingredient in several top selling hair regrowth products including Rogaine, Rogaine Extra Strength and Lipogaine. FDA registration of the product is expected to be completed within the next 90 days. The company expects to have the new product on the market later this year.
The company has chosen Nupelo as the brand name for its new hair regrowth product. ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023.
ViaDerma’s President & CEO, Dr. Chris Otiko stated: “Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both.”
$VDRM What a monster! Over 250% and going!#OTC pic.twitter.com/KsKO71Hfm6
— PikachOTC (@PikachOTC) March 17, 2023
For More on VDRM Subscribe Right Now!
Currently trading at a $13 million market valuation VDRM os is 1,023,620,662 with around 911,600,265 shares in the public float. The Company has a decent balance sheet with little assets and $2.5 million in liabilities on the books. VDRM is an exciting story developing in small caps; Viaderma continues to make progress recently launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra. Viaderma also expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. ViaDerma receives $5,000 per month for each state in which the licensee is doing business and the new states increases ViaDerma’s current royalties to $55,000 per month from this agreement. More recently Viaderma submitted its application for its planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and the Company expects this process to be completed within a few weeks. We will be updating on VDRM when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in VDRM either long or short and we have not been compensated for this article.
